Becton Dickinson (BDX) announced that the BD Onclarity HPV Assay has officially been added to the American Society for Colposcopy and Cervical Pathology, or ASCCP, enduring risk-based management guidelines, due to its ability to individually identify more high-risk types of HPV.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson Appoints New Chief Accounting Officer
- Becton Dickinson names Pamela Spikner chief accounting officer
- Becton Dickinson price target lowered to $275 from $290 at Evercore ISI
- Citi analysis yields ‘substantial upside’ in Becton Dickinson shares
- Becton Dickinson discloses resolution with SEC over Alaris System invesigation